Who we are

Vector Vitale is creating a breakthrough class of isotope-selective medicines that provide symmetry correction of biomolecules including amino acids, polypeptides and proteins, and can be re-dosed to provide a sustainable effect. We have a strong team of like-minded specialists with expertise in physics, chemistry, technology and life sciences.
We were founded in 2015 after more than 20 years of extensive research in mathematical models of hierarchical stable systems, physics of the atom, and isotope-induced phase transitions in biomolecules.

Our interdisciplinary studies lead to novel methods for prevention and treatment of degenerative diseases.

B uilding on these discoveries, we have created our isotope-selective therapeutic platform. The initial therapeutic application of our isotope-selective medicines is focused at the prevention and treatment of diabetes, obesity, several types of solid malignant tumors and Parkinson’s disease.

Our vision

Our vision is to change the paradigm of treatment for patients with degenerative diseases by addressing the fundamental factors defining the onset and progress of pathologies. We aim to change how the degenerative diseases are defined.

Wiki: Degenerative disease is the result of a continuous process based on degenerative cell changes, affecting tissues or organs, which will increasingly deteriorate over time unless stopped or reversed.

We are working towards our goal by further developing core pharmaceutical compositions to create medicines covering unmet needs of patients with a broad spectrum of degenerative diseases.

Our plan is to make the treatment readily available to people ages 25 – 40 years old to maximize the preventative effect and exclude the probability of degenerative disorders later in life.

New Principles of Therapy

Our technology is based on the consideration of the human organism as a complex hierarchical multi-level stable system with a network of negative feedback.
The origin of degenerative diseases is unknown because in such a system degeneration occurs below the current border of life sciences. It starts on the level of amino acids and chemical elements and can’t be controlled by homeostasis. The interplay in the chain (protein – chiral biomolecules – isotopes) is a key factor defining the onset of pathogenesis. The type of resulting degenerative disease depends on the type of isotopes, amino acids and proteins at the source where it starts.

Wrong chirality of amino acids inside proteins is related to a wrong conformation. A wrong conformation of proteins creates damaged receptors and signaling pathways, non-functional key-lock mechanisms and crash of negative feedback starting from the cellular level. Malfunctional homeostasis is a key feature of every degenerative disease.

T he positive aspect is that at all the variety of pathological changes, the core algorithm of the pathogenesis is the same. It provides an opportunity for treatment and prevention of all degenerative diseases. The methods of treatment are based on the use of interconnection between differential and integral components of stable systems, as well as on the possibility to control its integrity from the bottom up, starting from sublevels (isotopes – amino acids – proteins) and (amino acids – proteins – cells).

High efficacy and the absence of harmful side effects are the hallmarks of our medicine.

The key elements of our technology:

  • Control of amino acids chirality in proteins
  • Correction of proteins conformation
  • Restoration of homeostasis in live cells

Pipeline

V ector Vitale is working to create medicines that treat the most challenging types of degenerative diseases. Our current R&D efforts are focused on finding the most efficient therapeutic solutions for Diabetes, Obesity, Parkinson’s disease and various types of cancer.

  • Solid Malignant Tumors
Description

Delivery Mode – IV injections
Commercial Rights – Vector Vitale Inc.

  • Blood cancers
Description

Delivery Mode – IV injections
Commercial Rights – Vector Vitale Inc.

  • Diabetes 1&2
Description

Delivery Mode – IV injections, Oral
Commercial Rights – Vector Vitale Inc.

  • Parkinson Disease
Description

Delivery Mode – IV injections, Oral
Commercial Rights – Vector Vitale Inc.

  • Solid Malignant Tumors
Description

Delivery Mode – IV injections
Commercial Rights – Vector Vitale Inc.

  • Blood cancers
Description

Delivery Mode – IV injections
Commercial Rights – Vector Vitale Inc.

  • Diabetes 1&2
Description

Delivery Mode – IV injections, Oral
Commercial Rights – Vector Vitale Inc.

  • Parkinson Disease
Description

Delivery Mode – IV injections, Oral
Commercial Rights – Vector Vitale Inc.

Contact Us

1 + 11 =

© Copyright 2018 – Vector Vitale